Drug eluting stents: managing coronary artery stenosis following PTCA

Garces K
Record ID 32002000925
English, French
Authors' objectives:

To summarise the available evidence on using drug eluting stents (DES) for managing coronary artery stenosis following percutaneous transluminal coronary angioplasty (PTCA).

Authors' recommendations: - Drug eluting stents (DES) release drugs that inhibit tissue growth in narrowed coronary arteries in an effort to prevent restenosis, a renarrowing of the artery. - Several types of DES are under investigation in clinical trials; however, none are currently approved for use in Canada. - Preliminary trial data are encouraging, demonstrating greater lumen diameter and reduced restenosis with DES versus uncoated stents. - If DES prove to be more effective than uncoated stents in the treatment and/or prevention of restenosis, this technology may diffuse rapidly. The total health care costs, including the cost of the stents, post-intervention therapy and possible re-intervention costs, will require assessment to determine the ultimate impact of DES.
Authors' methods: Overview
Project Status: Completed
URL for project: https://www.ccohta.ca/
Year Published: 2002
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Coronary Stenosis
  • Costs and Cost Analysis
  • Stents
Organisation Name: Canadian Coordinating Office for Health Technology Assessment
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name: requests@cadth.ca
Contact Email: requests@cadth.ca
Copyright: Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.